| Docetaxel-related side effects and their management J Baker, J Ajani, F Scotté, D Winther, M Martin, MS Aapro, ... European journal of oncology nursing 13 (1), 49-59, 2009 | 321 | 2009 |
| Bone health in cancer: ESMO clinical practice guidelines R Coleman, P Hadji, JJ Body, D Santini, E Chow, E Terpos, S Oudard, ... Annals of oncology 31 (12), 1650-1663, 2020 | 313 | 2020 |
| Managing cancer patients during the COVID-19 pandemic: an ESMO multidisciplinary expert consensus G Curigliano, S Banerjee, A Cervantes, MC Garassino, P Garrido, ... Annals of Oncology 31 (10), 1320-1335, 2020 | 304 | 2020 |
| Efficacy of venlafaxine for the prevention and relief of oxaliplatin-induced acute neurotoxicity: results of EFFOX, a randomized, double-blind, placebo-controlled phase III trial JP Durand, G Deplanque, V Montheil, JM Gornet, F Scotte, O Mir, ... Annals of Oncology 23 (1), 200-205, 2012 | 254 | 2012 |
| Multicenter study of a frozen glove to prevent docetaxel-induced onycholysis and cutaneous toxicity of the hand F Scotté, JM Tourani, E Banu, M Peyromaure, E Levy, S Marsan, ... Journal of clinical oncology 23 (19), 4424-4429, 2005 | 226 | 2005 |
| European Society for Medical Oncology (ESMO) position paper on supportive and palliative care K Jordan, M Aapro, S Kaasa, CI Ripamonti, F Scotté, F Strasser, A Young, ... Annals of Oncology 29 (1), 36-43, 2018 | 203 | 2018 |
| Systemic anticancer therapy-induced peripheral and central neurotoxicity: ESMO–EONS–EANO Clinical Practice Guidelines for diagnosis, prevention, treatment and follow-up B Jordan, A Margulies, F Cardoso, G Cavaletti, HS Haugnes, P Jahn, ... Annals of Oncology 31 (10), 1306-1319, 2020 | 177 | 2020 |
| Pegylated liposomal doxorubicin-associated hand–foot syndrome: recommendations of an international panel of experts R Von Moos, BJK Thuerlimann, M Aapro, D Rayson, K Harrold, J Sehouli, ... European journal of cancer 44 (6), 781-790, 2008 | 174 | 2008 |
| Diagnosis, assessment and management of constipation in advanced cancer: ESMO Clinical Practice Guidelines PJ Larkin, NI Cherny, D La Carpia, M Guglielmo, C Ostgathe, F Scotté, ... Annals of oncology 29, iv111-iv125, 2018 | 165 | 2018 |
| Multicenter randomized phase II study of two schedules of docetaxel, estramustine, and prednisone versus mitoxantrone plus prednisone in patients with metastatic hormone … S Oudard, E Banu, P Beuzeboc, E Voog, LM Dourthe, AC Hardy-Bessard, ... Journal of clinical oncology 23 (15), 3343-3351, 2005 | 162 | 2005 |
| Platelet microparticles: a potential predictive factor of survival in hormone-refractory prostate cancer patients treated with docetaxel-based chemotherapy D Helley, E Banu, A Bouziane, A Banu, F Scotte, AM Fischer, S Oudard European urology 56 (3), 479-485, 2009 | 135 | 2009 |
| Addressing the quality of life needs of older patients with cancer: a SIOG consensus paper and practical guide F Scotté, P Bossi, E Carola, T Cudennec, P Dielenseger, F Gomes, ... Annals of Oncology 29 (8), 1718-1726, 2018 | 130 | 2018 |
| A Fluorospot assay to detect single T lymphocytes simultaneously producing multiple cytokines A Gazagne, E Claret, J Wijdenes, H Yssel, F Bousquet, E Levy, P Vielh, ... Journal of immunological methods 283 (1-2), 91-98, 2003 | 125 | 2003 |
| Determinants of the outcomes of patients with cancer infected with SARS-CoV-2: results from the Gustave Roussy cohort L Albiges, S Foulon, A Bayle, B Gachot, F Pommeret, C Willekens, ... Nature Cancer 1 (10), 965-975, 2020 | 123 | 2020 |
| Matched case‐control phase 2 study to evaluate the use of a frozen sock to prevent docetaxel‐induced onycholysis and cutaneous toxicity of the foot F Scotté, E Banu, J Medioni, E Levy, C Ebenezer, S Marsan, A Banu, ... Cancer 112 (7), 1625-1631, 2008 | 119 | 2008 |
| Collecting duct carcinoma of the kidney: a clinicopathological study of 9 cases M Peyromaure, N Thiounn, F Scotté, A Vieillefond, B Debre, S Oudard The Journal of urology 170 (4), 1138-1140, 2003 | 111 | 2003 |
| Role of physical activity and sport in oncology: scientific commission of the National Federation Sport and Cancer CAMI T Bouillet, X Bigard, C Brami, K Chouahnia, L Copel, S Dauchy, ... Critical reviews in oncology/hematology 94 (1), 74-86, 2015 | 100 | 2015 |
| Expression and mutational status of treatment-relevant targets and key oncogenes in 123 malignant salivary gland tumours J Cros, E Sbidian, S Hans, H Roussel, F Scotté, E Tartour, D Brasnu, ... Annals of oncology 24 (10), 2624-2629, 2013 | 92 | 2013 |
| Impact and management of chemotherapy/radiotherapy-induced nausea and vomiting and the perceptual gap between oncologists/oncology nurses and patients: a cross-sectional … C Vidall, P Fernández-Ortega, D Cortinovis, P Jahn, B Amlani, F Scotté Supportive Care in Cancer 23, 3297-3305, 2015 | 88 | 2015 |
| Prostate-specific antigen doubling time before onset of chemotherapy as a predictor of survival for hormone-refractory prostate cancer patients S Oudard, E Banu, F Scotte, A Banu, J Medioni, P Beuzeboc, F Joly, ... Annals of oncology 18 (11), 1828-1833, 2007 | 86 | 2007 |
Roger von MoosHead of medical Oncology Cantonal Hospital GraubuendenAdresse e-mail validée de ksgr.ch
